Drug Trial Radar · NCT06190951
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma
Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
151
Actual
Start
Sep 18, 2024
Primary completion
Nov 2, 2026
Study completion Dec 9, 2030
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jan 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with cemiplimab alone. These types of immunotherapy study drugs are collectively known as immune checkpoint inhibitors. Immunotherapies are treatments that use the immune system to recognize and kill cancer cells. The study is focused on participants with a type of skin cancer known as melanoma. The objective of this study is to see if the combination of fianlimab and cemiplimab is an effective treatment compared to cemiplimab in participants with high-risk, resectable melanoma. Participants will receive treatment before surgery, undergo resection, and then will have the option to continue treatment after resection. The study is looking at several other research questions, including: * What side effects may happen from receiving the study drug(s). * How much study drug(s) is in the blood at different times. * Whether the body makes antibodies against the study drug(s) (which could make the drug less effective or could lead to side effects). Antibodies are proteins that are naturally found in the blood stream that fight infections. * How administering the study drugs might improve quality of life.
Conditions
- Melanoma
Interventions
cemiplimabDrug
Administered per the protocol
Fixed Dose Combination (FDC) cemiplimab+fianlimabDrug
Or coadministration, depending on availability.
PlaceboDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological complete response (pCR) rate as assessed by Blinded Independent Pathological Review (BIPR)Time frame: Up to 1 year
Locations
104 sites in 8 countries. Site status is shown where the registry gives one.
UC San Diego
La Jolla, California
USC Norris Comprehensive Cancer Center
Los Angeles, California
Hoag Family Cancer Institute
Newport Beach, California
California Pacific Medical Center Research Institute
San Francisco, California
University of California San Francisco (UCSF)
San Francisco, California
St John's Cancer Institute
Santa Monica, California
University of Colorado Cancer Center
Aurora, Colorado
Hartford Hospital
Hartford, Connecticut
Yale University Cancer Center
New Haven, Connecticut
Emory Healthcare, Emory Clinic
Atlanta, Georgia
NorthShore University HealthSystem
Evanston, Illinois
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute Brookline Avenue
Boston, Massachusetts
University of Massachusetts Chan Medical School
Worcester, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Northwell Health Cancer Institute
Lake Success, New York
Duke Cancer Institute, University Hospital
Durham, North Carolina
Seidman Cancer Center
Cleveland, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio
The Ohio State University James Comprehensive Cancer Center
Columbus, Ohio
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
University of Tennessee Medical Center
Knoxville, Tennessee
UT Southwestern/Simmons Comprehensive Cancer Center
Dallas, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas
University of Virginia
Charlottesville, Virginia
Inova Schar Cancer Institute
Fairfax, Virginia
Lismore Base Hospital
Lismore, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Melanoma Institute of Australia
Wollstonecraft, New South Wales, Australia
The Townsville Hospital
Douglas, Queensland, Australia
Hervey Bay Hospital
Hervey Bay, Queensland, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
The Queen Elizabeth Hospital
Woodville, South Australia, Australia
Icon Cancer Centre Hobart
Hobart, Tasmania, Australia
Eastern Health
Box Hill, Victoria, Australia
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
One Clinical Research at Hollywood Private Hospital
Nedlands, Western Australia, Australia
Medical University of Vienna
Vienna, Austria
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.